NCT07702097

Brief Summary

The goal of this interventional study (clinical trial) is to check if ajwa seed powder can treat type 2 diabetes mellitus in overweight and and obese patients with type 2 diabetes mellitus including both male and female of the age group between 30-50. The main question is what would be the impact of ajwa seed powder on HbA1c and body composition in overweight and obese patients with type 2 diabetes mellitus which aim to result in better glycemic control particular Hba1c, and body composition improvement in type 2 diabetes mellitus patients Participants will be asked to consume 4 grams of ajwa seed powder per day

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
10mo left

Started Jun 2026

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress17%
Jun 2026Jun 2027

First Submitted

Initial submission to the registry

May 6, 2026

Completed
26 days until next milestone

Study Start

First participant enrolled

June 1, 2026

Completed
1 month until next milestone

First Posted

Study publicly available on registry

July 14, 2026

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2027

Last Updated

July 14, 2026

Status Verified

June 1, 2026

Enrollment Period

1 year

First QC Date

May 6, 2026

Last Update Submit

July 9, 2026

Conditions

Obesity & OverweightType 2 Diabetes (T2DM)

Keywords

Type 2 diabetes mellitusHbA1cAjwa seed powderObesityBody composition

Outcome Measures

Primary Outcomes (1)

  • change in HbA1c concentration (%) from baseline to week 12 in 30 overweight and obese patients with type 2 diabetes mellitus

    12 weeks

Secondary Outcomes (6)

  • Weight in kg

    12 weeks

  • Height in meter

    12 weeks

  • Waist circumference in cm

    12 weeks

  • Hip circumference in cm

    12 weeks

  • Fat free mass in kg

    12 weeks

  • +1 more secondary outcomes

Study Arms (1)

Ajwa Seed powder group

OTHER

This will be Single Arm interventional Study in which overweight or obese adults aged 30-50 years with Type 2 Diabetes (HbA1c \>6.5% and BMI 25-35 kg/m²) will receive Ajwa seed powder supplementation (4 g/day in the form of capsules or sachets) for 12 weeks. HbA1c levels and body composition parameters, including body weight, BMI, waist/hip circumference, fat mass, fat-free mass, visceral fat, and muscle mass, will be assessed before and after the intervention using an InBody bioelectrical impedance analyzer.

Dietary Supplement: Ajwa Seed powder

Interventions

Ajwa Seed powderDIETARY_SUPPLEMENT

The intervention in this study is Ajwa (Phoenix dactylifera) seed powder, a natural plant-based product obtained from Ajwa dates. It is distinguished from other clinical interventions by its botanical origin, absence of chemical modification, and standardized preparation process, which includes cleaning, drying, and grinding into a uniform powder form. A fixed dose is administered to all participants in the intervention arm according to the study protocol. Unlike pharmaceutical or biologic interventions, it is a non-pharmacological dietary supplement intended for metabolic support. The intervention specifically targets HbA1c levels and body composition in diabetic and/or obese individuals, with no additional experimental treatments included. This controlled and standardized approach differentiates it from other clinical or nutritional interventions.

Ajwa Seed powder group

Eligibility Criteria

Age30 Years - 50 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Age: 30-50 years
  • Gender: Male/female
  • Body Mass Index (BMI): 25-35 kg/m²

You may not qualify if:

  • Patients being treated with insulin
  • High initial levels of serum creatinine (men\>1.5 mg/dl; women\>1.2 mg/dl)
  • Pregnant/lactating females or women who cannot take proper contraceptive measures
  • Symptoms consistent with peptic ulcer disease or history of peptic ulcers
  • Active cancer patients
  • Severe non-diabetes-related illnesses
  • Patients with heart, liver, or lung failures
  • Patients with blood disorders or on anticoagulant drugs such as warfarin Any other disease as decided by the principal investigator, which might put the safety of the subjects at risk while conducting the test

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sultan Hospital

Sheikhupura, 39359, Pakistan

Location

MeSH Terms

Conditions

ObesityOverweightDiabetes Mellitus, Type 2

Condition Hierarchy (Ancestors)

OvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and SymptomsDiabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesEndocrine System Diseases

Study Officials

  • Dr. Waqas Ahmad

    UVAS

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Nimrah Tahir, Mphil food and nutrition

CONTACT

+923314568232nimrahtahir1999@gmail.com

Dr. Waqas Ahmad

CONTACT

+92 333 5950108waqas.niaz@uvas.edu.pk

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 6, 2026

First Posted

July 14, 2026

Study Start

June 1, 2026

Primary Completion (Estimated)

June 1, 2027

Study Completion (Estimated)

June 1, 2027

Last Updated

July 14, 2026

Record last verified: 2026-06

Data Sharing

IPD Sharing
Will share

Locations

PA(1)